PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
2017; Elsevier BV; Volume: 129; Issue: 23 Linguagem: Inglês
10.1182/blood-2017-01-764209
ISSN1528-0020
AutoresLakshmi Nayak, Fábio M. Iwamoto, Ann S. LaCasce, Srinivasan Mukundan, Margaretha G.M. Roemer, Bjoern Chapuy, Philippe Armand, Scott J. Rodig, Margaret A. Shipp,
Tópico(s)Vascular Tumors and Angiosarcomas
ResumoKey Points Genetic analysis reveals frequent 9p24.1/PD-L1/PD-L2 copy-number alterations and increased expression of the PD-1 ligands in PCNSL and PTL. PD-1 blockade with nivolumab demonstrated activity in patients with relapsed/refractory PCNSL and PTL.
Referência(s)